Literature DB >> 17721108

Virological fitness of HIV in patients with resistance to enfuvirtide.

Doris Chibo1, Norman Roth, Vanessa Roulet, Katharina Skrabal, Megan Gooey, Louise Carolan, Jodie Nicholls, Anastasia Papadakis, Chris Birch.   

Abstract

Resistance to the HIV fusion inhibitor enfuvirtide is associated with mutations in the first heptad repeat region of gp41, but little is known of their impact on replicative fitness in vivo. We followed seven patients undergoing salvage therapy that included enfuvirtide in order to document the temporal generation of genotypic and phenotypic resistance in parallel with replicative fitness. Resistance to enfuvirtide was not associated with decreased replicative fitness of HIV strains infecting these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721108     DOI: 10.1097/QAD.0b013e3282ef1bc8

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.

Authors:  Janis A Müller; Anna Glöckle; Ali Gawanbacht; Matthias Geyer; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

2.  Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.

Authors:  Kazuya Shimura; Daisuke Nameki; Keiko Kajiwara; Kentaro Watanabe; Yasuko Sakagami; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Stefan G Sarafianos; Eiichi N Kodama
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

3.  Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene.

Authors:  Jeanne Kowalski; Stephen J Gange; Michael F Schneider; Hua-Ling Tsai; Alan Templeton; Qiujia Shao; Guang Wen Zhang; Mei-Fen Yeh; Mary Young; Richard B Markham
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

4.  Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Authors:  Dirk Eggink; Christopher E Baldwin; Yiqun Deng; Johannes P M Langedijk; Min Lu; Rogier W Sanders; Ben Berkhout
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

Review 5.  Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review.

Authors:  N Wagner; C A Wyler-Lazarevic; S Yerly; C Samer; G Peytavin; K M Posfay-Barbe; A Calmy; J Ambrosioni
Journal:  New Microbes New Infect       Date:  2015-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.